Compare Novo Nordisk A/S (NVO) vs Vanguard S&P 500 Growth Index Fund ETF (VOOG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Vanguard S&P 500 Growth Index Fund ETF — how do they compare? Novo Nordisk A/S trades at $49.35 (market cap $220.53B), while Vanguard S&P 500 Growth Index Fund ETF trades at $82.03. The key difference: Novo Nordisk A/S pays a 3.63% dividend while Vanguard S&P 500 Growth Index Fund ETF pays none, and Vanguard S&P 500 Growth Index Fund ETF is trading nearer its 52-week high, Novo Nordisk A/S nearer its low. Which is the better fit depends on your goals.
| NVO | VOOG | |
|---|---|---|
Market Cap | $220.53B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $71.70 | $85.11 |
52-Week Low | $35.29 | $65.32 |
Enterprise Value | $239.49B | — |
Dividend Yield | 3.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
VOOG, the Vanguard S&P 500 Growth ETF, trades at $80.98, up 0.28% on the day. The technical outlook is bearish with moving averages signaling selling pressure, though oscillators are neutral. Recent news highlights its competitive expense ratio of 0.07% and heavy technology sector concentration, which has driven strong long-term returns but also introduces volatility. A 1:6 stock split occurred on April 21, 2026, and a small dividend is scheduled for June 26, 2026.
The ETF's outlook hinges on the performance of large-cap growth stocks, particularly in technology. Opportunities exist from continued AI-driven growth, but risks include high sector concentration and market sensitivity to tech valuations. Analyst sentiment is generally positive given its low-cost structure and historical performance, though the current bearish technical signal warrants caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Vanguard S&P 500 Growth Index Fund ETF
VOOG is an index-based ETF that tracks the S&P 500 Growth Index, composed of the growth-oriented companies within the S&P 500. It selects constituents based on three key metrics—sales growth, the ratio of earnings change to price, and momentum—offering a highly liquid and low-cost way to capture the high-performing 'growth slice' of the broader U.S. large-cap market.
Read more on VOOG →
